Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of BNT324, a B7-H3 antibody-drug conjugate, with BNT327, a bispecific antibody targeting PD-L1 and VEGF, in adults with advanced or metastatic small cell lung cancer SCLC and non-small cell lung cancer NSCLC. This two-part Phase IbII trial aims to find safe dose levels, optimize dosing, and assess preliminary efficacy and safety in various lung cancer patient groups. Participants in Part 1 receive escalating doses of BNT324 with BNT327 to determine recommended dose levels. Part 2 compares these dose levels in randomized cohorts of treatment-naive NSCLC and relapsed SCLC patients, with additional cohorts receiving the optimal dose to further evaluate efficacy and safety. Treatments are given via intravenous infusion, and dosing is adjusted based on safety and response data. Throughout the study, participants undergo screening, treatment, safety follow-up, and long-term survival monitoring. Researchers assess dose-limiting toxicities, adverse events, objective response rates, disease control, progression-free survival, and overall survival. Treatment effects are evaluated up to 87 months, with close monitoring for side effects and treatment tolerability during and after therapy.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating a new medicine called GSK5764227 designed to deliver a toxin directly to cancer cells to destroy them while sparing healthy cells. This study tests the combination of GSK5764227 with standard treatments for advanced solid tumors, including metastatic colorectal cancer and metastatic castration-resistant prostate cancer. The purpose is to assess the safety, how the body processes the drug, immune responses triggered, and its ability to shrink or control cancer. Participants receive GSK5764227 along with other drugs such as bevacizumab, fluorouracil, leucovorin, or enzalutamide depending on the cancer type. The study is non-randomized and conducted in a sequential model with different cohorts for the cancer types. Treatment and assessments occur over up to approximately 31 weeks for safety and up to 112 weeks for extended monitoring of drug levels, immune response, and cancer control measures. During the study, participants will be monitored for adverse events, dose tolerability, and changes in vital signs, laboratory tests, and cardiac function. Researchers will also measure drug concentration in plasma, immune antibody formation, and evaluate cancer response rates and progression-free survival. The total participation may last several years with ongoing evaluations, and all activities are conducted under medical supervision to track safety and clinical activity.
Actively Recruiting
Researchers are evaluating how well LY3537021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy in adults with cancer. This phase 2 study compares LY3537021 with a placebo, both given along with standard anti-nausea medicines. The study focuses on adults who have not previously received chemotherapy and are planned to receive specific types of chemotherapy drugs. Participants receive either LY3537021 or placebo as a subcutaneous injection before chemotherapy, along with standard antiemetic treatments taken by mouth, intravenously, or through skin patches, depending on local guidelines. The chemotherapy drugs used include cisplatin or anthracycline with cyclophosphamide administered intravenously. The study uses a double-blind and randomized design to compare the two groups. Throughout the study, participants are monitored for nausea and vomiting during the period from the start of chemotherapy through 120 hours after the first infusion. Researchers assess the proportion of participants who have a complete response, meaning no vomiting and no need for additional rescue medication, particularly in the delayed phase. Participants remain in the study for about two months until all parts are completed, including safety evaluations and pharmacokinetic measurements.
Actively Recruiting
Researchers are evaluating new treatments for acute hypoxemic respiratory failure AHRF, a serious lung condition affecting millions worldwide and often leading to death or long-term health issues. This adaptive platform trial tests different interventions across varying severity levels, including non-intubated patients, those on mechanical ventilation, and patients needing extracorporeal life support. The study uses an advanced Bayesian design to efficiently assess multiple therapies and strategies, focusing on improving outcomes for critically ill patients. The trial includes several domains studying various therapies such as ultra-protective ventilation with extracorporeal CO2 removal, different mechanical ventilation strategies, corticosteroid use, and new drug treatments like fludrocortisone and nebulized furosemide. Interventions may involve adjusting ventilator settings, sedation, rehabilitation, or medication dosing over periods ranging from days to weeks. Some domains are observational and collect detailed biomarker and clinical data. The platform allows adding or dropping interventions based on ongoing results, optimizing research efficiency. Participants will undergo regular assessments including physiological and biological measurements, respiratory function tests, and monitoring of clinical outcomes like mortality, ventilator-free days, and organ function scores. Safety and adherence to protocols are closely tracked throughout. The study duration varies by intervention, with some domains enrolling patients over two years and monitoring outcomes up to six months. Participants may experience multiple visits for treatment adjustments, data collection, and follow-up evaluations.
Actively Recruiting
This research evaluates the effectiveness of a personalized, stepped, multidisciplinary intervention delivered through a virtual multimodal rehabilitation hub for adults undergoing colorectal cancer surgery. The study aims to reduce postoperative complications within 30 days after surgery compared to usual care. Secondary goals include assessing quality of life, recovery quality, days spent at home after surgery, cost-effectiveness, and implementation metrics. Participants are randomly assigned to either the virtual multimodal hub intervention or usual care. The intervention includes tailored exercise, nutritional, psychological, nursing support, and peer support groups before and after surgery. The frequency and type of support are individualized and delivered virtually, with tablets provided if needed. The intervention may continue up to 12 months post-surgery, while the control group receives usual care without additional virtual support. Participants are screened and consented before surgery, followed by baseline assessments and randomization. Throughout the study, researchers monitor postoperative complications, quality of life, recovery, days at home, resource use, and implementation outcomes at multiple time points up to 12 months after surgery. Safety is overseen by an independent committee to ensure participant well-being during the approximately 60-month study period.
Actively Recruiting
This research is focused on patients with acute severe brain injuries, such as those caused by stroke, traumatic injury, or oxygen loss after cardiac arrest, who require mechanical ventilation. It evaluates whether giving a single dose of a commonly used antibiotic soon after intubation can prevent infections in the airways and lungs, known as pneumonia, which is a common complication in these patients. The study aims to improve survival and recovery chances by preventing these infections early. Participants are randomly assigned to receive either a single intravenous dose of 2 grams of ceftriaxone diluted in at least 200 mL of 0.9% sodium chloride or a placebo an intravenous infusion of 0.9% sodium chloride without ceftriaxone shortly after intubation. This is a double-blind trial, meaning neither participants nor researchers know who receives the antibiotic or placebo. The treatment is given once shortly after the breathing tube is inserted. During the study, participants will be monitored for 90 days to measure overall survival and for 180 days to assess functional outcomes related to brain injury recovery. Researchers will collect data on survival rates, neurological function, length of mechanical ventilation, need for reintubation or tracheostomy, and other related health measures. The study also monitors safety and evaluates if antibiotic use affects outcomes and antibiotic resistance over time.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
The trial investigates treatments for bloodstream infection caused by Staphylococcus aureus SAB, which can be life-threatening with a 15-30% death rate within three months. This international, multi-center randomized adaptive platform trial aims to find the best treatment options to reduce mortality within 90 days of infection. The trial adapts over time by assigning more patients to treatments that show better outcomes and removing less effective options. Participants receive various antibiotic treatments depending on their group. These include intravenous vancomycin or daptomycin, flucloxacillin or cloxacillin, cefazolin, or benzylpenicillin, with dosages adjusted for kidney function or illness severity. Some receive adjunctive drugs like clindamycin, and others may switch from intravenous to oral antibiotics if eligible after 7 or 14 days. Additionally, some participants undergo PETCT scans as part of the study. During the study, participants are monitored closely with blood cultures, temperature checks, and clinical assessments to track infection clearance and complications. Researchers measure all-cause mortality at 90 days as the primary outcome, along with other outcomes such as survival at earlier time points, hospital stay length, microbiological treatment failure, serious reactions, and antibiotic use. Safety and health economic data are also collected to evaluate treatments comprehensively throughout the trial.
Actively Recruiting
Researchers are evaluating ORIC-944, a selective small molecule inhibitor targeting PRC2, in patients with metastatic prostate cancer. This open-label, phase 11b study aims to establish the safety and preliminary antitumor activity of ORIC-944 both alone and combined with androgen receptor pathway inhibitors ARPIs. The study involves patients who have progressed after prior ARPI therapies and explores dose escalation and optimization across different patient groups. Participants receive ORIC-944 orally once daily in 28-day continuous cycles either alone or combined with ARPIs such as abiraterone, apalutamide, darolutamide, or enzalutamide. The study has three parts Part I tests ORIC-944 alone Part II tests combinations with ARPIs Part III optimizes dosing of ORIC-944 with ARPIs in separate cohorts. Future combinations with abiraterone or enzalutamide may also be explored. During the study, participants undergo assessments including skin and tumor biopsies and monitoring of organ function and performance status. Researchers measure drug concentrations in the blood, antitumor responses, progression-free survival, and PSA levels. Safety and activity are evaluated over months, with follow-up for up to 36 months. The trial is sponsored by ORIC Pharmaceuticals and runs from 2022 to 2028.
1-10 of 13
1